Keros Therapeutics (KROS) Competitors

$11.22 +0.24 (+2.19%)

Closing price 04:00 PM Eastern

Extended Trading

$11.20 -0.02 (-0.13%)

As of 04:10 PM Eastern

KROS vs. SDGR, LBRX, MGTX, XNCR, and PHAR

Should you buy Keros Therapeutics stock or one of its competitors? MarketBeat compares Keros Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Keros Therapeutics include Schrodinger (SDGR), LB Pharmaceuticals (LBRX), MeiraGTx (MGTX), Xencor (XNCR), and Pharming Group (PHAR). These companies are all part of the "pharmaceutical products" industry.

How does Keros Therapeutics compare to Schrodinger?

Keros Therapeutics (NASDAQ:KROS) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Keros Therapeutics presently has a consensus price target of $20.40, indicating a potential upside of 81.82%. Schrodinger has a consensus price target of $20.25, indicating a potential upside of 53.06%. Given Keros Therapeutics' higher possible upside, equities analysts clearly believe Keros Therapeutics is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Schrodinger has a net margin of -40.61% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -17.04% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-17.04%	-15.84%
Schrodinger	-40.61%	-30.85%	-15.32%

Keros Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Schrodinger has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

Keros Therapeutics has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.91	$87.01M	-$3.01	N/A
Schrodinger	$255.87M	3.82	-$103.26M	-$1.41	N/A

In the previous week, Keros Therapeutics had 6 more articles in the media than Schrodinger. MarketBeat recorded 11 mentions for Keros Therapeutics and 5 mentions for Schrodinger. Schrodinger's average media sentiment score of -0.30 beat Keros Therapeutics' score of -0.33 indicating that Schrodinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Schrodinger	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 20.6% of Keros Therapeutics shares are owned by company insiders. Comparatively, 10.1% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Schrodinger beats Keros Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to LB Pharmaceuticals?

Keros Therapeutics (NASDAQ:KROS) and LB Pharmaceuticals (NASDAQ:LBRX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

71.6% of Keros Therapeutics shares are owned by institutional investors. 20.6% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

LB Pharmaceuticals has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. LB Pharmaceuticals' return on equity of 0.00% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-17.04%	-15.84%
LB Pharmaceuticals	N/A	N/A	N/A

Keros Therapeutics has higher revenue and earnings than LB Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.91	$87.01M	-$3.01	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A

In the previous week, Keros Therapeutics had 9 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 11 mentions for Keros Therapeutics and 2 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.67 beat Keros Therapeutics' score of -0.33 indicating that LB Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
LB Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Keros Therapeutics presently has a consensus price target of $20.40, suggesting a potential upside of 81.82%. LB Pharmaceuticals has a consensus price target of $38.40, suggesting a potential upside of 37.14%. Given Keros Therapeutics' higher possible upside, analysts plainly believe Keros Therapeutics is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

LB Pharmaceuticals beats Keros Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Keros Therapeutics compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Keros Therapeutics has higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	10.80	-$114.20M	-$1.48	N/A
Keros Therapeutics	$244.06M	0.91	$87.01M	-$3.01	N/A

MeiraGTx presently has a consensus price target of $25.83, indicating a potential upside of 172.22%. Keros Therapeutics has a consensus price target of $20.40, indicating a potential upside of 81.82%. Given MeiraGTx's stronger consensus rating and higher probable upside, equities research analysts plainly believe MeiraGTx is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

MeiraGTx has a net margin of -151.12% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -17.04% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	-1,065.47%	-54.96%
Keros Therapeutics	-256.60%	-17.04%	-15.84%

MeiraGTx has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 7.5% of MeiraGTx shares are owned by company insiders. Comparatively, 20.6% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Keros Therapeutics had 4 more articles in the media than MeiraGTx. MarketBeat recorded 11 mentions for Keros Therapeutics and 7 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.40 beat Keros Therapeutics' score of -0.33 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Keros Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MeiraGTx beats Keros Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Keros Therapeutics compare to Xencor?

Keros Therapeutics (NASDAQ:KROS) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Keros Therapeutics presently has a consensus price target of $20.40, suggesting a potential upside of 81.82%. Xencor has a consensus price target of $24.50, suggesting a potential upside of 117.39%. Given Xencor's stronger consensus rating and higher possible upside, analysts clearly believe Xencor is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Keros Therapeutics has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.91	$87.01M	-$3.01	N/A
Xencor	$125.58M	6.65	-$91.92M	-$2.29	N/A

Keros Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Xencor has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

Xencor has a net margin of -177.10% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -17.04% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-17.04%	-15.84%
Xencor	-177.10%	-28.77%	-20.52%

71.6% of Keros Therapeutics shares are held by institutional investors. 20.6% of Keros Therapeutics shares are held by insiders. Comparatively, 4.8% of Xencor shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Keros Therapeutics had 8 more articles in the media than Xencor. MarketBeat recorded 11 mentions for Keros Therapeutics and 3 mentions for Xencor. Xencor's average media sentiment score of 0.75 beat Keros Therapeutics' score of -0.33 indicating that Xencor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xencor	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Keros Therapeutics beats Xencor on 9 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Keros Therapeutics has lower revenue, but higher earnings than Pharming Group. Keros Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.41	$2.85M	$0.16	80.06
Keros Therapeutics	$244.06M	0.91	$87.01M	-$3.01	N/A

Pharming Group has a net margin of 3.30% compared to Keros Therapeutics' net margin of -256.60%. Pharming Group's return on equity of 4.64% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	3.30%	4.64%	2.55%
Keros Therapeutics	-256.60%	-17.04%	-15.84%

Pharming Group presently has a consensus target price of $38.33, indicating a potential upside of 199.25%. Keros Therapeutics has a consensus target price of $20.40, indicating a potential upside of 81.82%. Given Pharming Group's stronger consensus rating and higher possible upside, research analysts clearly believe Pharming Group is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 20.6% of Keros Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Keros Therapeutics had 11 more articles in the media than Pharming Group. MarketBeat recorded 11 mentions for Keros Therapeutics and 0 mentions for Pharming Group. Pharming Group's average media sentiment score of 0.00 beat Keros Therapeutics' score of -0.33 indicating that Pharming Group is being referred to more favorably in the media.

Company	Overall Sentiment
Pharming Group	Neutral
Keros Therapeutics	Neutral

Pharming Group has a beta of 0.04, indicating that its stock price is 96% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

Summary

Pharming Group beats Keros Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Keros Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KROS vs. The Competition

Export

Metric	Keros Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$222.04M	$3.36B	$6.34B	$12.29B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-3.73	19.01	20.92	25.47
Price / Sales	0.91	278.84	521.15	73.36
Price / Cash	2.19	125.35	43.18	55.00
Price / Book	0.78	6.90	9.98	7.00
Net Income	$87.01M	$24.23M	$3.55B	$335.16M
7 Day Performance	2.09%	0.58%	0.40%	-0.29%
1 Month Performance	-0.80%	-0.61%	-0.02%	1.18%
1 Year Performance	-20.09%	63.26%	34.94%	34.78%

Keros Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KROS Keros Therapeutics	2.6047 of 5 stars	$11.22 +2.2%	$20.40 +81.8%	-22.3%	$222.04M	$244.06M	N/A	100	Earnings Report Analyst Revision
SDGR Schrodinger	2.8073 of 5 stars	$12.62 -1.0%	$20.25 +60.5%	-42.8%	$941.27M	$255.87M	N/A	790
LBRX LB Pharmaceuticals	2.1991 of 5 stars	$31.41 -2.8%	$37.20 +18.4%	N/A	$926.54M	N/A	N/A	16
MGTX MeiraGTx	2.9685 of 5 stars	$9.95 -0.2%	$25.67 +158.0%	+74.2%	$922.96M	$81.39M	N/A	300	News Coverage Earnings Report Insider Trade
XNCR Xencor	2.1472 of 5 stars	$11.88 -4.0%	$24.50 +106.2%	+39.1%	$917.87M	$125.58M	N/A	280

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KROS) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Keros Therapeutics (KROS) Competitors

KROS vs. SDGR, LBRX, MGTX, XNCR, and PHAR

How does Keros Therapeutics compare to Schrodinger?

Summary

How does Keros Therapeutics compare to LB Pharmaceuticals?

Summary

How does Keros Therapeutics compare to MeiraGTx?

Summary

How does Keros Therapeutics compare to Xencor?

Summary

How does Keros Therapeutics compare to Pharming Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS vs. The Competition

Keros Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Keros Therapeutics (KROS) Competitors

KROS vs. SDGR, LBRX, MGTX, XNCR, and PHAR

How does Keros Therapeutics compare to Schrodinger?

Do analysts prefer KROS or SDGR?

Is KROS or SDGR more profitable?

Which has more volatility and risk, KROS or SDGR?

Which has better valuation & earnings, KROS or SDGR?

Does the media prefer KROS or SDGR?

Do insiders and institutionals believe in KROS or SDGR?

Summary

How does Keros Therapeutics compare to LB Pharmaceuticals?

Do insiders & institutionals hold more shares of KROS or LBRX?

Is KROS or LBRX more profitable?

Which has better valuation & earnings, KROS or LBRX?

Does the media prefer KROS or LBRX?

Do analysts prefer KROS or LBRX?

Summary

How does Keros Therapeutics compare to MeiraGTx?

Which has stronger valuation and earnings, MGTX or KROS?

Do analysts prefer MGTX or KROS?

Is MGTX or KROS more profitable?

Which has more volatility & risk, MGTX or KROS?

Do insiders and institutionals believe in MGTX or KROS?

Does the media favor MGTX or KROS?

Summary

How does Keros Therapeutics compare to Xencor?

Do analysts recommend KROS or XNCR?

Which has stronger earnings and valuation, KROS or XNCR?

Which has more volatility & risk, KROS or XNCR?

Is KROS or XNCR more profitable?

Do institutionals & insiders believe in KROS or XNCR?

Does the media prefer KROS or XNCR?

Summary

How does Keros Therapeutics compare to Pharming Group?

Which has better valuation and earnings, PHAR or KROS?

Is PHAR or KROS more profitable?

Do analysts recommend PHAR or KROS?

Do institutionals and insiders believe in PHAR or KROS?

Does the media favor PHAR or KROS?

Which has more risk and volatility, PHAR or KROS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS vs. The Competition

Keros Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools